• 1
    Howe HL,Wingo PA,Thun MJ,Ries LA,Rosenberg HM,Feigal EG,Edwards BK. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93: 82442.
  • 2
    Levi F,Lucchini F,Negri E,La Vecchia C. Trends in mortality from non-Hodgkin's lymphomas. Leuk Res 2002; 26: 9038.
  • 3
    Jemal A,Clegg LX,Ward E,Ries LA,Wu X,Jamison PM,Wingo PA,Howe HL,Anderson RN,Edwards BK. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 2004; 101: 327.
  • 4
    Levi F,Lucchini F,Negri E,Boyle P,La Vecchia C. Cancer mortality in Europe, 1995–1999, and an overview of trends since 1960. Int J Cancer 2004; 110: 15569.
  • 5
    World Health Organization Statistical Information System. WHO mortality database. 2007. Available at:
  • 6
    World Health Organization. International classification of disease: 8th revision. Geneva: World Health Organization, 1967.
  • 7
    World Health Organization. International classification of disease: 9th revision. Geneva: World Health Organization, 1977.
  • 8
    World Health Organization. International statistical classification of disease and related health problems: 10th revision. Geneva: World Health Organization, 1992.
  • 9
    Doll R,Smith PG. Comparison between registries: age-standardized rates, vol. IV. In: WaterhouseJAH,MuirCS,ShanmugaratnamK,PowellJ,PeachamD,WhelanS, eds.Cancer incidence in five continents. Lyon: IARC, 1982. 6715. IARC Sci Publ No. 42.
  • 10
    Parkin DM,Whelan SL,Ferlay J,Storm H. Cancer incidence in five continents, vol. I–VIII. [Cancer base No. 7]. Lyon, France: International Agency for Research on Cancer, 2005.
  • 11
    Engholm G,Storm HH,Ferlay J,Christensen C,Bray F,Ólafsdóttir E,Pukkala E,Talbäk M. NORDCAN: cancer incidence and mortality in the Nordic countries, Version 3.0. Association of Nordic cancer registries.Danish Cancer Society. 2007. Available at:
  • 12
    Swedish cancer registry. Available at:
  • 13
    Information services division (ISD). Available at:
  • 14
    National statistics. Available at:
  • 15
    Dutch comprehensive cancer centres. Available at:
  • 16
    Institute of oncology Ljubljana. Available at:
  • 17
    National cancer registry Ireland. Available at:
  • 18
    Eltom MA,Jemal A,Mbulaiteye SM,Devesa SS,Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002; 94: 120410.
  • 19
    Bray I,Brennan P,Boffetta P. Recent trends and future projections of lymphoid neoplasms—a Bayesian age-period-cohort analysis. Cancer Causes Control 2001; 12: 81320.
  • 20
    Adamson P,Bray F,Costantini AS,Tao MH,Weiderpass E,Roman E. Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer 2007; 43: 391401.
  • 21
    Sandin S,Hjalgrim H,Glimelius B,Rostgaard K,Pukkala E,Askling J. Incidence of non-Hodgkin's lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was. Cancer Epidemiol Biomarkers Prev 2006; 15: 1295300.
  • 22
    Armitage JO,Bierman PJ,Bociek RG,Vose JM. Lymphoma 2006: classification and treatment. Oncology (Williston Park) 2006; 20: 2319; discussion 42, 44, 49.
  • 23
    Turesson I,Zettervall O,Cuzick J,Waldenstrom JG,Velez R. Comparison of trends in the incidence of multiple myeloma in Malmo, Sweden, and other countries, 1950–1979. N Engl J Med 1984; 310: 4214.
  • 24
    Harris NL,Jaffe ES,Diebold J,Flandrin G,Muller-Hermelink HK,Vardiman J. Lymphoma classification—from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol 2000; 11 ( Suppl 1): 310.
  • 25
    Jaffe E,Harris NL,Stein H,Vardiman J. World Health Organization Classification of Tumours: pathology and genetics of tumours of hematopoietic and lymphoid tissue. Lyon, France: IARC, 2001.
  • 26
    Gil-Delgado MA,Khyat D,Johnson SAN. Chapter 30. Lymphomas. In: PollockRE, ed. UICC manual of clinical oncology,8th edn. New Jersey: Wiley, 2004. 67189.
  • 27
    Hartge P,Devesa SS,Fraumeni JF,Jr. Hodgkin's and non-Hodgkin's lymphomas. Cancer Surv 1994; 19–20: 42353.
  • 28
    Hartge P,Wang SS,Bracci PM,Devesa SS,Holly EA. Non-Hodgkin lymphoma. In: SchottenfeldD,FraumeniJF, Jr, eds. Cancer epidemiology and prevention,3rd edn. New York: Oxford University Press, 2006. 898918.
  • 29
    Gail MH,Pluda JM,Rabkin CS,Biggar RJ,Goedert JJ,Horm JW,Sondik EJ,Yarchoan R,Broder S. Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst 1991; 83: 695701.
  • 30
    Dal Maso L,Rezza G,Zambon P,Tagliabue G,Crocetti E,Vercelli M,Zanetti R,Falcini F,Tonini G,Mangone L,De Lisi V,Ferretti S, et al. Non-Hodgkin lymphoma among young adults with and without AIDS in Italy. Int J Cancer 2001; 93: 4305.
  • 31
    Negri E,Little D,Boiocchi M,La Vecchia C,Franceschi S. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004; 111: 18.
  • 32
    Dal Maso L,Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006; 15: 207885.
  • 33
    Jepsen P,Vilstrup H,Tarone RE,Friis S,Sorensen HT. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. Int J Cancer 2007; 121: 16246.
  • 34
    Goodnough LT,Brecher ME,Kanter MH,AuBuchon JP. Transfusion medicine. First of two parts—blood transfusion. N Engl J Med 1999; 340: 43847.
  • 35
    Polesel J,Talamini R,Montella M,Parpinel M,Dal Maso L,Crispo A,Crovatto M,Spina M,La Vecchia C,Franceschi S. Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case-control study. Ann Oncol 2006; 17: 71318.
  • 36
    Koutros S,Zhang Y,Zhu Y,Mayne ST,Zahm SH,Holford TR,Leaderer BP,Boyle P,Zheng T. Nutrients contributing to one-carbon metabolism and risk of non-hodgkin lymphoma subtypes. Am J Epidemiol 2008; 167: 28794.
  • 37
    Levi F,Randimbison L,Te VC,Franceschi S,La Vecchia C. Trends in survival for patients diagnosed with cancer in Vaud, Switzerland, between 1974 and 1993. Ann Oncol 2000; 11: 95763.
  • 38
    Zinzani PL,Tani M,Pulsoni A,Gobbi M,Perotti A,De Luca S,Fabbri A,Zaccaria A,Voso MT,Fattori P,Guardigni L,Ronconi S, et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008; 9: 3528.
  • 39
    Blum KA,Bartlett NL. Antibodies for the treatment of diffuse large cell lymphoma. Semin Oncol 2003; 30: 44856.
  • 40
    Vose JM,Bierman PJ,Loberiza FR,Lynch JC,Bociek GR,Weisenburger DD,Armitage JO. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 2008; 14: 3642.
  • 41
    Han X,Kilfoy B,Zheng T,Holford TR,Zhu C,Zhu Y,Zhang Y. Lymphoma survival patterns by WHO subtype in the United States, 1973–2003. Cancer Causes Control 10.1007/s10552-008-9147-4.
  • 42
    Sant M,Allemani C,De Angelis R,Carbone A,de Sanjose S,Gianni AM,Giraldo P,Marchesi F,Marcos-Gragera R,Martos-Jimenez C,Maynadie M,Raphael M, et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 2008; 44: 57987.